
    
      To support anidulafungin NDA in China Due to the challenges in subject recruitment resulting
      in protracted study course, Pfizer Inc. has decided to terminate trial A8851023 prematurely
      based on the recommendation by the senior management team on November 8, 2011. The decision
      to terminate the trial was not based on any safety concerns. All investigators were verbally
      informed by the study team since November 8, 2011 to stop the subject recruitment as soon as
      possible. All 17 enrolled subjects have been followed up on safety issues and no safety
      concerns were present by the data of these subjects.
    
  